P4373 - Understanding Patient Preferences at the Time of Treatment Escalation to First Line Advanced Therapies in Ulcerative Colitis: A Discrete Choice Experiment in Five European Countries

Award: Presidential Poster Award

Stefan Schreiber, MD¹, Alissa Walsh, MD², Peter Hur, PharmD³, Laura Panattoni, PhD⁴, Brett Hauber, ³, Grace Gahlon, ⁴, Josh Coulter, PhD³, Karolina Wosik, MSc, PhD⁵, Joseph C. Cappelleri, PhD, MPH⁶, Natalie Land, PhD⁴, Xiang Guo, PharmD, MS⁷, Anthony Buisson, MD, PhD^8
1University Hospital, Kiel, Schleswig-Holstein, Germany; ²Translational Gastroenterology Unit, Oxford University Hospital, Oxford, England, United Kingdom; ³Pfizer Inc., New York, NY; ⁴PRECISIONheor, New York, NY; ⁵Pfizer Canada, Kirkland, PQ, Canada; ⁶Pfizer Inc., Groton, CT; ⁷Pfizer Inc., Collegeville, PA; ⁸University Hospital Estaing, Clermont Auvergne University, Inserm U1071, M2iSH, USC-INRA 2018, Clermont-Ferrand, Auvergne, France

Introduction: Patients with moderately to severely active ulcerative colitis (UC) escalating from conventional therapy (CT) to advanced therapy (AT) often consider several treatment factors. As more AT options become available, understanding the treatment preferences of AT naïve patients will enhance shared decision making with clinicians.

Methods: We conducted an online, cross-sectional survey of patients in the EU and UK with self-reported moderately to severely active UC who were diagnosed ≥ 3 months ago, had history of CT use (5-ASA, steroids, or immunomodulators), and did not report history of AT use. A discrete choice experiment (DCE) was used to quantify patient preferences for attributes associated with first-line AT for UC, including efficacy, safety, and mode and frequency of administration. Each patient completed 12 DCE choice tasks. Preference weights were estimated for all attribute levels using a random parameters logit model. Attribute relative importance (RI; range 0−100%) was calculated using the difference in preference weights between the most and least preferred level of each attribute to summarize the relative influence of each attribute on treatment choice.

Results: 514 patients, with a mean age of 44.0 years, were included. The majority had a university degree (73.0%), were employed full-time (53.7%), diagnosed with UC ≤ 5 years ago (76.1%), and had a mean (SD) Patient Modified Simple Clinical Colitis Activity Index score of 4.9 (3.3; score range 0−19; a score of < 3 is generally defined as remission). All DCE attributes factored into patient treatment decisions (Table: RI and preference weights). However, probability of remission at 1 year had the strongest influence on patients’ treatment preferences (RI: 46.2%) followed by 5-year risk of cancer (RI: 11.0%), annual risk of a major adverse cardiovascular event (RI: 10.9%) and time to symptom improvement (RI: 8.5%). Oral formulations with the same dose throughout were preferred over injection or infusion options (Table).

Discussion: In patients with moderate to severe UC and no reported history of AT use, probability of remission at 1 year, followed by 5-year risk of cancer, were the most important attributes influencing treatment choice, though all attributes tested had some impact. These findings will help to highlight to clinicians the trade-offs between efficacy, safety, and administration mode that patients make when considering AT choices. This is becoming increasingly important as more treatment options become available.


Disclosures:


Stefan Schreiber, MD¹, Alissa Walsh, MD², Peter Hur, PharmD³, Laura Panattoni, PhD⁴, Brett Hauber, ³, Grace Gahlon, ⁴, Josh Coulter, PhD³, Karolina Wosik, MSc, PhD⁵, Joseph C. Cappelleri, PhD, MPH⁶, Natalie Land, PhD⁴, Xiang Guo, PharmD, MS⁷, Anthony Buisson, MD, PhD⁸. P4373 - Understanding Patient Preferences at the Time of Treatment Escalation to First Line Advanced Therapies in Ulcerative Colitis: A Discrete Choice Experiment in Five European Countries, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.